Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT)

JAMA

Volumn 288, Issue 23, 2002, Pages 2998-3007

  Furberg, Curt D ^c   Wright, Jackson T ^c   Davis, Barry R ^b   Cutler, Jeffrey A ^c   Alderman, Michael ^c   Black, Henry ^c   Cushman, William ^c   Grimm, Richard ^c   Haywood, L Julian ^c   Leenen, Frans ^c   Oparil, Suzanne ^c   Probstfield, Jeffrey ^a   Whelton, Paul ^c   Nwachuku, Chuke ^c   Gordon, David ^c   Proschan, Michael ^c   Einhorn, Paula ^c   Ford, Charles E ^c   Piller, Linda B ^c   Dunn, J Kay ^c   Goff, David ^c   Pressel, Sara ^c   Bettencourt, Judy ^c   DeLeon, Barbara ^c   Simpson, Lara M ^c   Blanton, Joe ^c   Geraci, Therese ^c   Walsh, Sandra M ^c   Nelson, Christine ^c   Rahman, Mahboob ^c   Juratovac, Anne ^c   Pospisil, Robert ^c   Carroll, Lillian ^c   Sullivan, Sheila ^c   Russo, Jeanne ^c   Barone, Gail ^c   Christian, Rudy ^c   Feldman, Sharon ^c   Lucente, Tracy ^c   Calhoun, David ^c   Jenkins, Kim ^c   McDowell, Peggy ^c   Johnson, Janice ^c   Kingry, Connie ^c   Alzate, Juan ^c   Margolis, Karen L ^c   Holland Klemme, Leslie Ann ^c   Jaeger, Brenda ^c   Williamson, Jeffrey ^c   Louis, Gail ^c   Ragusa, Pamela ^c   Williard, Angela ^c   Ferguson, R L Sue ^c   Tanner, Joanna ^c   Eckfeldt, John ^c   Crow, Richard ^c   Pelosi, John ^c   more..

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; STATINE DERIVATIVE; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; CANCER; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NORTH AMERICA; OUTCOMES RESEARCH; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0037132607     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.23.2998     Document Type: Article

References (27)

1. Gordon DJ. Cholesterol lowering and total mortality. In: Rifkind BM, ed. Contemporary Issues in Cholosterol Lowering: Clinical and Population Aspects. New York, NY: Marcel Dekker; 1995:33-48.
2. Davis BR, Cutler JA, Gordon DJ, et al, for the ALLHAT Research Group. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9:342-360.
3. LaRosa J, Applegate W, Crouse J, et al. Cholesterol lowering in the elderly: Results of the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. Arch Intern Med. 1994;154:529-539.
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344:1383-1389.
5. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333:1301-1307.
6. Sacks FM, Pfeffer MA, Moye LA, et al, for The Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
7. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
8. Downs JR, Clearfield M, Weis S, et al, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
9. Heart Protection Study Collaborative Group. MRC/ BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals. Lancet. 2002;360:7-22.
10. Post Coronary Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts N Engl J Med. 1997;336:153-162.
11. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first parcutaneous coronary intervention. JAMA. 2002;287:3215-3222.
12. LaRosa JC, He J, Vuppurturi S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA. 1999;282:2340-2346.
13. Gordon DJ. Cholesterol lowering reduces mortality. In: Grundy S, ed. Cholesterol Lowering Therapies. New York, NY: Marcel Dekker; 1999:299-311.
14. Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
15. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
16. Pressel S, Davis BR, Louis GT, et al, for the ALLHAT Collaborative Research Group. Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Control Clin Trials. 2001;22:674-686.
17. Wright JT, Cushman WC, Davis BR, et al, for the ALLHAT Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Clinical center recruitment experience. Control Clin Trials. 2001;22:659-673.
18. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. JAMA. 2000;283; 1967-1975.
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
20. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
21. International Classification of Diseases, Ninth Revision, Clinical Modification. Washington, DC: Public Health Service; 1988.
22. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Regression. New York, NY: Springer-Verlag; 1997.
23. Davis BR, Hardy RJ. Upper bounds for type I and II error rates in conditional power calculations. Commun Stat. 1990;19:3571-3584.
24. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:659-663.
25. Gordon DJ, Proschan MA, Rossouw JE. Cholesterol lowering and cardiovascular disease. Presented at: 6th International Symposium on Global Risk of Coronary Heart Disease and Stroke: Assessment, Prevention, and Treatment; Florence, Italy; June 12-15, 2002. Abstract and slides at Lorenzini Symposium Web site. Available at: http://www.lorenzinifoundation.org/gr2002/slides/ (search by author: Rossouw JE). Accessed November 2, 2002.
26. Corsini A, Bellosta S, Baetta R, Faumgalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999;84:413-428.
27. Sacks FM, Tonkin AM, Shepherd J, et al, for the Prospective Pravastatin pooling project. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. Circulation. 2000;102: 1893-1900.